FDA Approves Updated COVID-19 Vaccines for 2026-2027 Respiratory Season

The U.S. Food and Drug Administration (FDA) has granted regulatory approvals for updated 2026-2027 COVID-19 vaccine formulations from Pfizer/BioNTech, Moderna, and Novavax Partners. These updated vaccines are designed to target the JN.1-lineage XFG subvariant and are authorized for adults aged 65 and older, as well as individuals with underlying conditions that increase the risk of severe respiratory illness.